Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model

DNA and Cell Biology

Volumn 34, Issue 1, 2015, Pages 55-62

  Zhao, Hongmin ^a   Wei, Wei ^a   Sun, Yuhui ^a   Gao, Jianhua ^a   Wang, Qi ^a   Zheng, Jianhua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE 3; CISPLATIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CTNNB1 PROTEIN, HUMAN;

A2780 CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENICITY; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DDP CELL; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE MODEL; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANIMAL; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION; GENE SILENCING; GENETICS; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE, NUDE; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920387526     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2014.2626     Document Type: Article

References (32)

1. Aravantinos, G., and Pectasides, D. (2014). Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res 7, 57.
2. Arend, R.C., Londono-Joshi, A.I., Samant, R.S., Li, Y., Conner, M., Hidalgo, B., Alvarez, R.D., Landen, C.N., Straughn, J.M., and Buchsbaum, D.J. (2014). Inhibition of wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol Oncol 134, 112-120.
3. Arend, R.C., Londono-Joshi, A.I., Straughn, J.M., Jr., and Buchsbaum, D.J. (2013). The wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol 131, 772-779.
4. Baekelandt, M., Lehne, G., Trope, C.G., Szanto, I., Pfeiffer, P., Gustavssson, B., and Kristensen, G.B. (2001). Phase i/ii trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 19, 2983-2993.
5. Bansal, S. (2012). Using p53 to help diagnose ovarian cancer. South Asian J Cancer 1, 56-57.
6. Bernas, T., and Dobrucki, J. (2002). Mitochondrial and nonmitochondrial reduction of mtt: interaction of mtt with tmre, jc-1, and nao mitochondrial fluorescent probes. Cytometry 47, 236-242.
7. Bicaku, E., Xiong, Y., Marchion, D.C., Chon, H.S., Stickles, X.B., Chen, N., Judson, P.L., Hakam, A., Gonzalez-Bosquet, J., Wenham, R.M., Apte, S.M., Fulp, W., Cubitt, C.L., Chen, D.T., and Lancaster, J.M. (2012). In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer 106, 1967-1975.
8. Bodnar, L., Stanczak, A., Cierniak, S., Smoter, M., Cichowicz, M., Kozlowski, W., Szczylik, C., Wieczorek, M., and Lamparska-Przybysz, M. (2014). Wnt/beta-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res 7, 16.
9. Chambers, S.K., Chow, H.H., Janicek, M.F., Cragun, J.M., Hatch, K.D., Cui, H., Laughren, C., Clouser, M.C., Cohen, J.L., Wright, H.M., Abu Shahin, N., and Alberts, D.S. (2012). Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin Cancer Res 18, 2668-2678.
10. Condello, S., Morgan, C.A., Nagdas, S., Cao, L., Turek, J., Hurley, T.D., and Matei, D. (2014). Beta-catenin-regulated aldh1a1 is a target in ovarian cancer spheroids. Oncogene [Epub ahead of print]; DOI: 10.1038/onc.2014.178.
11. Conteduca, V., Kopf, B., Burgio, S.L., Bianchi, E., Amadori, D., and De Giorgi, U. (2014). The emerging role of anti-angiogenic therapy in ovarian cancer (review). Int J Oncol 44, 1417-1424.
12. Fan, L., Zhang, W., Yin, M., Zhang, T., Wu, X., Zhang, H., Sun, M., Li, Z., Hou, Y., Zhou, X., Lou, G., and Li, K. (2012). Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a uplc/qtof/ms platform. Acta Oncol 51, 473-479.
13. Furlong, M.T., and Morin, P.J. (2000). Rare activation of the tcf/beta-catenin pathway in ovarian cancer. Gynecol Oncol 77, 97-104.
14. Khrunin, A.V., Khokhrin, D.V., Moisseev, A.A., Gorbunova, V.A., and Limborska, S.A. (2014). Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics 15, 329-337.
15. Kildal, W., Risberg, B., Abeler, V.M., Kristensen, G.B., Sudbo, J., Nesland, J.M., and Danielsen, H.E. (2005). Beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer 41, 1127-1134.
16. Nam, E.J., Kim, J.W., Kim, J.H., Kim, S., Kim, S.W., Jang, S.Y., Lee, D.W., Jung, Y.W., and Kim, Y.T. (2010). Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. Am J Clin Oncol 33, 233-237.
17. Nawrocki, S.T., Kelly, K.R., Smith, P.G., Espitia, C.M., Possemato, A., Beausoleil, S.A., Milhollen, M., Blakemore, S., Thomas, M., Berger, A., and Carew, J.S. (2013). Disrupting protein neddylation with mln4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 19, 3577-3590.
18. Nishitani, H., Sugimoto, N., Roukos, V., Nakanishi, Y., Saijo, M., Obuse, C., Tsurimoto, T., Nakayama, K.I., Nakayama, K., Fujita, M., Lygerou, Z., and Nishimoto, T. (2006). Two e3 ubiquitin ligases, scf-skp2 and ddb1-cul4, target human cdt1 for proteolysis. EMBO J 25, 1126-1136.
19. Pakneshan, S., Safarpour, D., Tavassoli, F., and Jabbari B. (2014). Brain metastasis from ovarian cancer: a systematic review. J Neurooncol 11, 1-6.
20. Palacios, J., and Gamallo, C. (1998). Mutations in the betacatenin gene (ctnnb1) in endometrioid ovarian carcinomas. Cancer Res 58, 1344-1347.
21. Peng, L., Xu, Z., Zhou, Y., Yang, T., Liang, Z.Q., and Zhang, M. (2010). [effect of rosiglitazone on cells cycle, apoptosis and expression of skp2 and p27kip1 in hepatocellular carcinoma cell line]. Zhonghua Gan Zang Bing Za Zhi 18, 148-149.
22. Schulman, B.A., Carrano, A.C., Jeffrey, P.D., Bowen, Z., Kinnucan, E.R., Finnin, M.S., Elledge, S.J., Harper, J.W., Pagano, M., and Pavletich, N.P. (2000). Insights into scf ubiquitin ligases from the structure of the skp1-skp2 complex. Nature 408, 381-386.
23. Schwartz, D.R., Wu, R., Kardia, S.L., Levin, A.M., Huang, C.C., Shedden, K.A., Kuick, R., Misek, D.E., Hanash, S.M., Taylor, J.M., Reed, H., Hendrix, N., Zhai, Y., Fearon, E.R., and Cho, K.R. (2003). Novel candidate targets of betacatenin/t-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 63, 2913-2922.
24. Sillanpaa, S.M., Anttila, M.A., Voutilainen, K.A., Ropponen, K.M., Sironen, R.K., Saarikoski, S.V., and Kosma, V.M. (2006). Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int J Cancer 119, 1792-1799.
25. Stalberg, K., Svensson, T., Lonn, S., and Kieler, H. (2014). The influence of comorbidity on mortality in ovarian cancer patients. Gynecol Oncol 133, 298-303.
26. Surowiak, P., Materna, V., Maciejczyk, A., Pudelko, M., Markwitz, E., Spaczynski, M., Dietel, M., Zabel, M., and Lage, H. (2007). Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450, 279-285.
27. Sylvester, P.W. (2011). Optimization of the tetrazolium dye (mtt) colorimetric assay for cellular growth and viability. Methods Mol Biol 716, 157-168.
28. Trivers, K.F., Patterson, J.R., Roland, K.B., and Rodriguez, J.L. (2013). Issues of ovarian cancer survivors in the USA: a literature review. Support Care Cancer 21, 2889-2898.
29. Vanderpuye, V., and Yarney, J. (2007). Ovarian cancer: an analysis of forty-four patients at the national radiotherapy centre, accra-ghana. West Afr J Med 26, 93-96.
30. Wang, T., Li, Y., Tuerhanjiang, A., Wang, W., Wu, Z., Yuan, M., Maitituoheti, M., and Wang, S. (2014). Twist2 contributes to cisplatin-resistance of ovarian cancer through the akt/gsk-3beta signaling pathway. Oncol Lett 7, 1102-1108.
31. Wu, H., Wang, K., Liu, W., and Hao, Q. (2014). Pten overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating krt10 expression. Biochem Biophys Res Commun 444, 141-146.
32. Yoshioka, S., King, M.L., Ran, S., Okuda, H., MacLean, J.A., 2nd, McAsey, M.E., Sugino, N., Brard, L., Watabe, K., and Hayashi, K. (2012). Wnt7a regulates tumor growth and progression in ovarian cancer through the wnt/beta-catenin pathway. Mol Cancer Res 10, 469-482.